risedronic acid has been researched along with Kidney Diseases in 3 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Serum samples were obtained for 72 h after dosing, and urine samples were collected for 72 h after dosing and then periodically for 6 weeks." | 2.69 | Effect of renal function on risedronate pharmacokinetics after a single oral dose. ( Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Russell, DA; St Peter, JV; Thompson, GA, 2000) |
| "We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX." | 1.33 | Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamano, T | 2 |
| Fujii, N | 2 |
| Nagasawa, Y | 2 |
| Isaka, Y | 2 |
| Moriyama, T | 2 |
| Okada, N | 1 |
| Imai, E | 2 |
| Horio, M | 2 |
| Ito, T | 2 |
| Mikami, S | 1 |
| Hori, M | 1 |
| Mitchell, DY | 1 |
| St Peter, JV | 1 |
| Eusebio, RA | 1 |
| Pallone, KA | 1 |
| Kelly, SC | 1 |
| Russell, DA | 1 |
| Nesbitt, JD | 1 |
| Thompson, GA | 1 |
| Powell, JH | 1 |
2 trials available for risedronic acid and Kidney Diseases
| Article | Year |
|---|---|
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination | 2007 |
Effect of renal function on risedronate pharmacokinetics after a single oral dose.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Kidney; Kidney | 2000 |
1 other study available for risedronic acid and Kidney Diseases
| Article | Year |
|---|---|
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density | 2006 |